

**Specimen Collected: 16-Jun-23 15:56****VGKC Complex Antibody Panel w/ Rflx, CSF** | Received: 16-Jun-23 15:56 Report/Verified: 16-Jun-23 16:04

Procedure	Result	Units	Reference Interval
CASPR2 Ab IgG CBA-IFA Screen, CSF	<b>Detected</b> * t1 i1		[< 1:1]
LGI1 Ab IgG CBA-IFA Screen, CSF	<b>Detected</b> * t2 i2		[< 1:1]
Voltage-Gated Potassium Channel Ab, CSF	<b>5.0</b> # i3	pmol/L	[0.0-1.1]

**CASPR2 Ab IgG Titer by CBA-IFA, CSF** | Received: 16-Jun-23 15:56 Report/Verified: 16-Jun-23 16:04

Procedure	Result	Units	Reference Interval
CASPR2 Ab IgG CBA-IFA Titer, CSF	<b>1:160</b> * i4		[< 1:1]

**LGI1 Ab IgG Titer by CBA-IFA, CSF** | Received: 16-Jun-23 15:56 Report/Verified: 16-Jun-23 16:04

Procedure	Result	Units	Reference Interval
LGI1 Ab IgG CBA-IFA Titer, CSF	<b>1:40</b> * i5		[< 1:1]

**Interpretive Text**

- t1: 16-Jun-23 15:56 (CASPR2 Ab IgG CBA-IFA Screen, CSF)  
CASPR2 Antibody, IgG is detected. Titer results to follow.
- t2: 16-Jun-23 15:56 (LGI1 Ab IgG CBA-IFA Screen, CSF)  
LGI1 Antibody, IgG is detected. Titer results to follow.

**Test Information**

- i1: CASPR2 Ab IgG CBA-IFA Screen, CSF  
INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Screen, CSF

Contactin-associated protein-2 (CASPR2) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of CASPR2 IgG antibody is associated with a wide spectrum of clinical manifestations, including acquired neuromyotonia, limbic encephalitis, painful neuropathy, and Morvan syndrome. Tumors such as thymoma, small cell lung cancer, and other rarer tumors may occur. The full-spectrum of clinical disorders and tumors associated with the CASPR2 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes CASPR2 transfected cell lines for the detection and semiquantification of the CASPR2 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

- i2: LGI1 Ab IgG CBA-IFA Screen, CSF  
INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Screen, CSF

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

**Unless otherwise indicated, testing performed at:****ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 23-167-900158**Report Request ID:** 17763811**Printed:** 19-Jun-23 11:56

Page 1 of 3

**Test Information**

i2: LGI1 Ab IgG CBA-IFA Screen, CSF  
Leucine-rich, glioma-inactivated 1 protein (LGI1) IgG antibody may occur as part of the voltage-gated potassium channel (VGKC) complex antibodies.

The presence of LGI1 IgG antibody is mainly associated with limbic encephalitis, hyponatremia, and myoclonic movements. LGI1 IgG antibody is rarely associated with tumors but may occur infrequently in Morvan syndrome, neuromyotonia, and idiopathic epilepsy. The full-spectrum of clinical disorders associated with the LGI1 IgG antibody continues to be defined. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.

This indirect fluorescent antibody assay utilizes LGI1 transfected cell lines for the detection and semi-quantification of the LGI1 IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i3: Voltage-Gated Potassium Channel Ab, CSF  
INTERPRETIVE INFORMATION: Voltage-Gated Potassium Channel  
(VGKC) Antibody, CSF

Voltage-Gated Potassium Channel (VGKC) antibodies are associated with neuromuscular weakness as found in neuromyotonia (also known as Issacs syndrome) and Morvan syndrome. VGKC antibodies are also associated with paraneoplastic neurological syndromes and limbic encephalitis; however, VGKC antibody-associated limbic encephalitis may be associated with antibodies to leucine-rich, glioma-inactivated 1 protein (LGI1) or contactin-associated protein-2 (CASPR2) instead of potassium channel antigens. A substantial number of VGKC-antibody positive cases are negative for LGI1 and CASPR2 IgG autoantibodies, not all VGKC complex antigens are known. The clinical significance of this test can only be determined in conjunction with the patient's clinical history and related laboratory testing.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i4: CASPR2 Ab IgG CBA-IFA Titer, CSF  
INTERPRETIVE INFORMATION: CASPR2 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

i5: LGI1 Ab IgG CBA-IFA Titer, CSF  
INTERPRETIVE INFORMATION: LGI1 Ab IgG CBA-IFA Titer, CSF

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

**Unless otherwise indicated, testing performed at:**

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 23-167-900158

**Report Request ID:** 17763811

**Printed:** 19-Jun-23 11:56

Page 2 of 3

Patient Age/Sex:

Unknown

---

**Test Information**

i5: LGI1 Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

---

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

***Unless otherwise indicated, testing performed at:***

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 23-167-900158

**Report Request ID:** 17763811

**Printed:** 19-Jun-23 11:56

Page 3 of 3